Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Индукция мощного ответа нейтрализующих антител с помощью разработанных белковых наночастичных вакцин против SARS-CoV-2
John C. Kraft, Ralph Steven Baric, Miklós Guttman, Lisa E. Gralinski, Neil P. King, Marion Pepper, Paul Kellam, Lauren P. Carter, Cameron M. Chow, Alexandra C. Walls, David Veesler, DEBORAH HEYDENBURG FULLER, Helen Y. Chu, Rashmi Ravichandran, Marcos C. Miranda, Brooke Fiala, Alexandra Schäfer, Samuel P. Wrenn, Minh Nguyet Pham, Michael Murphy, Longping V. Tse, Laila Shehata, Megan A. O’Connor, Chengbo Chen, Mary Jane Navarro, Deleah Pettie, Cassandra Ogohara, Anne L. Palser, Sara Chalk, E-Chiang Lee, Kathryn A. Guerriero, Elizabeth Kepl, Claire Sydeman, Edgar A. Hodge, Brieann Brown, Jim Fuller, Kenneth H. Dinnon, Sarah R. Leist, Kendra L. Gully, Thomas B. Lewis, Kelly K. Lee, Timothy Patrick Sheahan, John C. Kraft
2020-10-31

SARS-CoV-2-RBD nanoparticle vaccineneutralizing antibody responsesreceptor-binding domainself-assembling protein nanoparticlesstructure-based vaccine design
A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower dose. Antibodies elicited by the nanoparticle immunogens target multiple distinct epitopes on the RBD, suggesting that they may not be easily susceptible to escape mutations, and exhibit a significantly lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the protein components and assembled nanoparticles, especially compared to the SARS-CoV-2 prefusion-stabilized S trimer, suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic.
1
High nanoparticle yield and stability indicated strong scalability for manufacturing, enabling cGMP efforts toward clinical development.
2
Nanoparticle-elicited antibodies targeted multiple distinct epitopes, potentially reducing susceptibility to viral escape mutations.
3
RBD nanoparticles induced neutralizing antibody titers 10-fold higher than prefusion-stabilized spike while using a 5-fold lower dose.
4
Structure-based self-assembling protein nanoparticles displaying 60 SARS-CoV-2 spike RBDs elicited potent protective antibody responses in mice.
5
The antibodies showed a lower binding-to-neutralizing ratio than convalescent human sera, potentially minimizing vaccine-associated enhanced respiratory disease risk.

Self-assembling protein nanoparticle vaccines displaying SARS-CoV-2 spike receptor-binding domains (RBDs)

The immunogenicity, neutralizing and protective antibody responses, epitope targeting, and manufacturability of the RBD nanoparticle vaccines

Publication Details
Publication Date
2020-10-31
Journal
Publisher
ISSN
Cited by
530
Access Type
Author Information
Authors
John C. Kraft
Ralph Steven Baric
Miklós Guttman
Lisa E. Gralinski
Neil P. King
Marion Pepper
Paul Kellam
Lauren P. Carter
Cameron M. Chow
Alexandra C. Walls
David Veesler
DEBORAH HEYDENBURG FULLER
Helen Y. Chu
Rashmi Ravichandran
Marcos C. Miranda
Brooke Fiala
Alexandra Schäfer
Samuel P. Wrenn
Minh Nguyet Pham
Michael Murphy
Longping V. Tse
Laila Shehata
Megan A. O’Connor
Chengbo Chen
Mary Jane Navarro
Deleah Pettie
Cassandra Ogohara
Anne L. Palser
Sara Chalk
E-Chiang Lee
Kathryn A. Guerriero
Elizabeth Kepl
Claire Sydeman
Edgar A. Hodge
Brieann Brown
Jim Fuller
Kenneth H. Dinnon
Sarah R. Leist
Kendra L. Gully
Thomas B. Lewis
Kelly K. Lee
Timothy Patrick Sheahan
John C. Kraft
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%